XGN - Exagen Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
23.50
-0.69 (-2.85%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close24.19
Open24.43
Bid19.00 x 900
Ask23.53 x 900
Day's Range22.93 - 24.43
52 Week Range11.54 - 29.86
Volume93,889
Avg. Volume82,306
Market Cap295.183M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-72.27
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est26.50
  • Do Hedge Funds Love Exagen Inc. (XGN)?
    Insider Monkey

    Do Hedge Funds Love Exagen Inc. (XGN)?

    Like everyone else, elite investors make mistakes. Some of their top consensus picks, such as Amazon, Facebook and Alibaba, have not done well in Q4 of 2018 due to various reasons. Nevertheless, the data show elite investors' consensus picks have done well on average over the long-term. The top 20 stocks among hedge funds beat […]

  • GlobeNewswire

    Exagen Announces Addition to Russell 3000® and 2000® Indexes

    Exagen Inc. (XGN), an organization dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention, today announced that it will be added to the Russell 3000® and 2000® Indexes, effective after the US market opens on December 23, 2019. Membership in the U.S. all-cap Russell 3000® Index, which remains in place for one year, means automatic inclusion in the small-cap Russell 2000® Index based on Exagen’s market capitalization. “We are pleased to have earned inclusion in the widely recognized Russell indexes,” said Ron Rocca, CEO of Exagen.

  • GlobeNewswire

    National Experts in Autoimmunity Tapped to Serve on Exagen’s Scientific Advisory Board

    Exagen Inc. (XGN), an organization dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention, today announced that it has formed a Scientific Advisory Board (SAB) consisting of national experts in the clinical management of rheumatic autoimmune diseases including rheumatoid arthritis and lupus. Ron Rocca, President and CEO at Exagen stated, “Our new scientific advisors will help guide the organization’s leadership team on the design and execution of research projects as well as weigh-in on known and anticipated advances in technologies affecting clinical management of autoimmune diseases.” Members of the SAB include; Dr. Arthur Weinstein, Dr. Joel Kremer, Dr. Anca Askanase, Dr. Andrew Concoff, Dr. Maureen McMahon, and Dr. Vasileios Kyttaris.

  • GlobeNewswire

    Exagen extends agreement with GSK for a third year to drive greater awareness about challenges facing lupus diagnosis and management

    Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention, today announced that it has extended its collaboration agreement with GlaxoSmithKline plc (GSK), one of the world’s leading healthcare companies, to raise awareness of the importance of timely diagnosis of systemic lupus erythematosus (SLE), the most common and severe form of lupus. At the center of the program are the proprietary AVISE laboratory tests, which can facilitate early diagnosis and management of SLE, a complex, incurable autoimmune disease.

  • GlobeNewswire

    Exagen Inc. Announces $26.2 Million Debt Refinancing

    Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention, announced today that it entered into an amendment to its loan and security agreement with its primary lender, an affiliate of Innovatus Capital Partners, LLC (“Innovatus”). Additional information regarding the amendment is available in the company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on November 21, 2019. “We are delighted to continue our support of Exagen in its pursuit of transforming the care for patients suffering from chronic autoimmune diseases,” said Claes Ekstrom, Managing Director at Innovatus.

  • GlobeNewswire

    Exagen Inc. to Participate in the 31st Annual Piper Jaffray Healthcare Conference on December 5, 2019

    SAN DIEGO, Nov. 20, 2019 -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from debilitating and chronic.

  • GlobeNewswire

    Exagen Inc. Reports Third Quarter 2019 Results

    AVISE® Testing Revenue Drives 27% Revenue Growth SAN DIEGO, Nov. 12, 2019 -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for.

  • GlobeNewswire

    Exagen to Participate in Canaccord Genuity 13th Annual MedTech & Diagnostics Forum on November 21, 2019

    SAN DIEGO, Nov. 07, 2019 -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from debilitating and chronic.

  • GlobeNewswire

    Exagen to Announce Third Quarter 2019 Financial Results on November 12th, 2019

    SAN DIEGO, Oct. 29, 2019 -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from debilitating and chronic.

  • GlobeNewswire

    Exagen Featured in Nine Scientific Presentations at 2019 ACR/ARHP Annual Meeting in Atlanta

    SAN DIEGO, Oct. 28, 2019 -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from debilitating and chronic.

  • GlobeNewswire

    Exagen to Be Honored with National Research Innovation Award by Lupus Foundation of America

    Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention, today announced that the Lupus Foundation of America will be recognizing their CEO Ron Rocca at the upcoming Evening of Hope Gala October 28. “We are humbled by this honor and grateful to the many internal and external clinical and scientific collaborators who contributed to the development of the AVISE® CTD panel,” said Ron Rocca, President and CEO of Exagen Inc. “We are closely aligned with the LFA in their mission to reduce the time to an accurate diagnosis of lupus, which is a key contributor to better control of the disease.  It is not acceptable that it takes an average of 6 years for an accurate diagnosis, or that lupus is the leading cause of death among women aged 15-24 with chronic inflammatory disease.

  • GlobeNewswire

    Exagen Announces Publication of Two Key Studies Validating Clinical Performance of AVISE® Lupus in Patients with Probable SLE and Demonstrating Superior Clinical Utility Compared to Standard Diagnostic Testing

    Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention, today announced the publication of two key studies. Collectively, the studies further validate that the information contained in the AVISE® Lupus test positively impacts physician clinical decision-making and demonstrated the patented test and algorithm helped predict those patients with early signs of systemic lupus erythematous (SLE) that are likely to transition to classifiable SLE according to American College of Rheumatology (ACR) criteria.

  • GlobeNewswire

    Exagen Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

    Exagen Inc. (Nasdaq: XGN),  an organization dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention, today announced the closing of its previously announced initial public offering of 4,140,000 shares of its common stock, which includes the exercise in full by the underwriters of their option to purchase 540,000 additional shares, at a public offering price of $14.00 per share. Registration statements relating to these securities have been filed with the Securities and Exchange Commission and became effective on September 18, 2019.

  • GlobeNewswire

    Exagen Inc. Announces Pricing of Initial Public Offering

    San Diego, CA, Sept. 18, 2019 -- Exagen Inc. (Nasdaq: XGN),  an organization dedicated to transforming the care continuum for patients suffering from debilitating and chronic.

  • Benzinga

    Exagen IPO: What You Need To Know

    A health care company, which develops diagnostic testing products for autoimmune disease, is eyeing a public listing this week. The IPO Terms Vista, California-based Exagen Inc. is planning to offer 3.33 ...